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Abstract
Background: There existed controversies about the association between the response to chemotherapy for
osteosarcoma (OS) patients and the genetic polymorphisms in excision repair cross-complementation group (ERCC1
and ERCC2) genes. We aimed to perform a meta-analysis to comprehensively evaluate the association.
Method: We searched multiple databases for literature retrieval including the PubMED (1966 ∼ 2017), Embase
(1980 ∼ 2017), and the Web of science (1945 ∼ 2017). The overall odds ratios(OR) and their corresponding 95%
confidence interval (CI) were calculated for the three polymorphisms under the dominant, recessive, and allelic
models.
Results: From six eligible articles in our study, we found that for ERCC1 rs11615 polymorphism, a significant
association was detected between the chemotherapy response and the polymorphism under all three models
(dominant model: OR = 2.015, P = 0.005; recessive model: OR = 1.791, P = 0.003; allelic model: OR = 1.677, P = 0.003),
and OS patients carrying C allele in rs11615 polymorphism were more likely to response to chemotherapy. In terms
of ERCC2 rs1799793 polymorphism, this polymorphism was significantly associated with the response to
chemotherapy for OS patients under recessive model (OR = 1.337, P = 0.036), and patients with AG + AA genotype
in rs1799793 polymorphism were more appropriate to receive chemotherapy. With respect to ERCC2 rs13181
polymorphism, this polymorphism was not correlated with the response to chemotherapy for OS patients under all
three models.
Conclusions: Our meta-analysis suggested that among Chinese population, the rs11615 and rs1799793
polymorphisms were significantly correlated with the response to chemotherapy for patients with OS, and patients
with CC or TC + CC genotypes in ERCC1 rs11615 polymorphism or AG + AA genotype in ERCC2 rs1799793
polymorphism were more suitable for chemotherapy.
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Background
Osteosarcoma, the most common primary malignancy of
bone, is a devastating disease due to its rapid dissemin-
ation and poor prognosis [1–3]. Approximately 60% of OS
sufferers are pediatric patients whose ages are ranged from
10 to 20 years old [4]. Patients with OS usually have some
clinical symptoms characterized by pain and swelling in
the affected bone, which is too intense and intolerable to
wake them from sleep [5]. There are 15–30% of cases who
have pulmonary metastasis when they are diagnosed as
OS, which frequently results in patient death [6].
The current well-established strategy for the treatment
of newly diagnosed OS was the combination of neoadju-
vant chemotherapy, surgical resection for metastatic OS
patients, and the adjuvant chemotherapy after surgery
[5]. The neoadjuvant therapy for OS is the combination
of cisplatin with doxorubicin, methotrexate, and ifosfa-
mide, which contributes to an improved 5-year survival
rate for patients without metastasis [7]. Among the
chemotherapy agents, cisplatin, a platinum analog which
can prevent cell division and growth by interfering with
DNA, is a commonly used treatment for various kinds
of tumors [8]. Moreover, accumulating large cooperative
group studies and international collaboration have docu-
mented cisplatin as one of the ideal agents of the effect-
ive combined chemotherapy for OS treatment [5].
The nucleotide excision repair (NER) pathway, a highly
powerful and sophisticated DNA damage removal path-
way, has been believed to play important roles in cancer
progression and response to platinum-based chemother-
apy [7, 9]. Excision repair cross-complementation groups
1 (ERCC1) and 2 (ERCC2) are genes encoding two key en-
zymes in NER pathway [10]. It has been reported that sin-
gle nucleotide polymorphisms (SNPs) of ERCC1 and
ERCC2 genes are associated with the response to chemo-
therapy for OS. A retrospective study showed that ERCC2
rs1799793, a DNA repair polymorphism, was a predictive
factor for chemotherapy response in OS patients [11]. A
study published on 2015 suggested that the polymorphism
of ERCC1 rs11615 affected on the response to chemother-
apy in OS treatment [12]. However, there is debate on the
predictive value of SNPs in ERCC1 and ERCC2 genes for
the response to chemotherapy for OS. Study from Yang et
al. found that polymorphism of ERCC1 rs11615 did not
significantly influence the response to chemotherapy in
patients with OS [13]. The ERCC2 rs1799793 polymorph-
ism has been proved to not be associated with the re-
sponse to chemotherapy for OS by a prospective study
[14]. Herein, in order to comprehensively evaluate the as-
sociation between the response to chemotherapy for OS
patients and the SNPs in ERCC1 and ERCC2 genes in-
cluding rs11615, rs1799793, and rs13181 polymorphisms,




The PubMED (1966 ∼ 2017), Embase (1980 ∼ 2017), and
the Web of science(1945 ∼ 2017) were searched for study
retrieval with a combination of Medical Subject Head-
ings (MeSH) and text words relating to “ERCC1”,
“ERCC2”, “osteosarcoma”, and “chemotherapy” as the
search strategy. We retrieved literatures from the data-
base inception to March 5th, 2017. The reference lists of
identified articles and related reviews were examined to
avoid any omission of eligible studies by the above elec-
tronic search strategy.
Inclusion and exclusion criteria
In order to get more reliable estimations, we pre-defined
strict inclusion criteria as follows: (1) all the participants
were OS patients treated with chemotherapy; (2) detect-
ing the relationship between the response to chemother-
apy, and the SNPs in ERCC1 and ERCC2 genes such as
rs11615, rs1799793, and rs13181 polymorphisms; (3)
studies conducted on Chinese population; (4) providing
available genotype data of relevant polymorphisms in
ERCC1 and ERCC2 genes; (5) full-text studies published
in English. Articles were eliminated if one of the follow-
ing existed: (1) other SNPs rather than rs11615,
rs1799793, and rs13181 polymorphisms; (2) SNPs of
ERCC1 and ERCC2 genes are risk factors for OS sur-
vival; (3) literature types such as news, books, communi-
cations, letters, and reviews.
Data extraction
The following data were collected independently from
incorporated studies by two reviewers according to the
mentioned inclusion and exclusion criteria: the first au-
thor, year of publication, number of patients, treatment
approaches, genotyping methods, the age and gender ra-
tio of patients, and genotyping data of ERCC1 rs11615,
ERCC2 rs1799793, and ERCC2 rs13181 polymorphisms.
Statistical analysis
We followed the Preferred Reporting Items for System-
atic reviews and Meta-Analyses (PRISMA) guidelines
[15]. In our study, the analyses were done with the
STATA 12 software (STATACorp LP, College Station,
TX, USA), and the value of P less than 0.05 was
regarded as statistically significant. The pooled odds ra-
tios (ORs) were calculated for dominant model, recessive
model, and allelic model for ERCC1 rs11615, ERCC2
rs1799793, and ERCC2 rs13181 polymorphisms, respect-
ively. The evaluation of response to chemotherapy was
identified as the previous relevant studies [12, 16, 17].
An OR > 1 refers less OS patients with poor response to
chemotherapy occur in the reference group, and patients
in reference group have higher response rate to
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chemotherapy. We firstly used the Mantel-Haenszel (M-
H) fixed-effects model to calculate the I2 index as assess-
ment of the heterogeneity among the incorporated
studies. If the I2 was less than 50%, we believed there
was no significant heterogeneity and adopted the fixed-
effects model to calculate the OR and its corresponding
95% CI. Otherwise, the DerSimonian and Laird (D-L)
random-effects model was selected for the calculation of
OR and 95% CI. Begg’s funnel plots were constructed to
examine the publication bias. The noticeable asymmetry
in the shape of funnel plot indicates publication bias.
Egger’s tests were performed for further investigation,
and the significance level was set at 0.05. The
Rosenthal’s fail-safe numbers were calculated to estimate
stability of the results [18]. The formula is as follows:
Nfs0.05 = (ΣZ/1.64)
2−n, where Z is Z scores for the indi-
vidual significance values, and n is the number of stud-
ies. A fail-safe number is often considered robust if it is
greater than 5n + 10 [19].
Results
Study characteristics
Based on our search strategy, we retrieved 56 literatures
from PUBMED, 86 from Embase, and 43 from the Web
of science. Twenty-five duplicated articles were removed,
leaving 130 literatures for further assessment. After
screening the titles, 54 literatures were eliminated. Then
the remaining 76 articles were estimated for eligibility
according to our inclusion and exclusion criteria. Finally
six eligible articles [12–14, 17, 20, 21] were included in
our meta-analysis. The flow diagram of study selection
process and reasons for exclusion was represented in
Fig. 1. Table 1 gives a summary of the characteristics of
each included study.
The relationship between the response to chemotherapy
for OS patients and the ERCC1 rs11615 polymorphism
Five studies including 1019 OS patients were incorpo-
rated to evaluate the association of the rs11615 poly-
morphism and the response to chemotherapy. The
results could be found in Table 2. For dominant (TT
+ TC versus CC) and allelic models (T versus C), the
random effects model was chosen to calculate the OR
and 95% CI due to the large heterogeneity. The ORs
for TT + TC versus CC and T versus C were 2.015
and 1.677, respectively (TT + TC versus CC: 95%
CI:1.242–3.271, P = 0.005, Fig. 2; T versus C: 95% CI:
1.194–2.356, P = 0.003, Fig. 2), which suggested that
significant association was detected between the
rs11615 polymorphism and the response to chemo-
therapy for OS patients under the dominant and al-
lelic models, and there were more responders to
chemotherapy in patients with CC genotype in
rs11615 polymorphism. With regard to the recessive
model (TT versus CC + TC), considering the small
heterogeneity, we selected the fixed-effects model to
yield the OR for this model. The OR for TT versus
CC + TC was 1.791 (95% CI:1.353–2.372, P = 0.003,
Fig. 2), revealing that the rs11615 polymorphism was
significantly associated with the response to chemo-
therapy for OS patients under recessive model, and
patients with CC + TC genotype in rs11615 poly-
morphism had higher response rate to chemotherapy.
Fig. 1 Flow diagram displaying study selection and specific reasons for exclusion from the mete-analysis
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The relationship between the response to chemotherapy
for OS patients and the ERCC2 rs13181 polymorphism
All eligible studies together pooled 1133 OS patients in-
volved in the association of the response to chemotherapy
and the rs13181polymorphism. Table 2 gave a summary of
the results. The values of I2were lower than 50% for all the
three models, so the fixed-effects model was used to
achieve the OR and 95% CI. The ORs for dominant model
(AA +AC versus CC), recessive model (AA versus AC +
CC), and allelic model (A versus C) were 1.058 (95% CI:
0.793–1.516, P = 0.757, Fig. 3), 1.135 (95% CI: 0.868–
1.484, P = 0.355, Fig. 3) and 1.091 (95% CI: 0.894–1.331, P
= 0.392, Fig. 3), respectively, which demonstrated that no
significant association was found between the rs13181
polymorphism and the response to chemotherapy for OS
patients under all the three models.
The relationship between the response to chemotherapy
for OS patients and the ERCC2 rs1799793 polymorphism
There were five eligible studies for the analysis of associ-
ation between the rs1799793 polymorphism and the re-
sponse to chemotherapy for OS patients. The results were
displayed in Table 2. For the dominant (GG +GA versus
AA) and recessive models (GG versus AG+AA), the
fixed-effects model was adopted for the estimation of OR
and 95% CI. The ORs for GG+GA versus AA and GG
versus AG+AA were 1.54 (95% CI: 0.982–2.413, P = 0.06,
Fig. 4) and 1.337 (95% CI: 1.019–1.754, P = 0.036, Fig. 4),
respectively, suggesting that the rs1799793 polymorphism
was significantly associated with the response to chemo-
therapy for OS patients under recessive model, and pa-
tients with GG genotype in rs179973 polymorphism had
poor response to chemotherapy. In terms of the allelic
model, the I2 was 57.60%, so the random effects model
was applied for yielding the OR and 95% CI. The OR for
G versus A was 1.328 (95% CI: 0.943–1.87, Fig. 4), and the
P was higher than 0.05, which implied that no significant
association was observed under allelic model.
Publication bias
We observed no obvious asymmetry in the shape of fun-
nel plots (Figs. 5, 6 and 7), referring that there was no
significant publication bias in the analyses. Moreover, all
the values of P in both Begg’s and Egger’s test were
higher than 0.05, which further provided evidence of no
publication bias in our study. Rosenthal’s fail-save num-
ber suggested that the results in allelic model of rs11615
groups and all three rs1799793 groups were compara-
tively reliable. However, the publication bias could not
be ignored in dominant model and recessive model of
rs11615 groups, and all three rs13181 groups (Table 2).
Discussion
In the current study, we performed a meta-analysis to
assess the association of the response to chemotherapy
for OS patients and the rs11615, rs1799793 and rs13181
polymorphisms. Our results showed that for
ERCC1rs11615, OS patients carrying CC or TC + CC ge-
notypes were more likely to respond to the chemother-
apy, and patients with C allele in rs11615 polymorphism
were more appropriate to receive chemotherapy. With
respect to ERCC2 rs1799793, the response rate to
chemotherapy in patients with AG +AA genotype was
significantly higher than that in patients carrying GG
genotype, and patients carrying AG +AA genotype in
rs1799793 polymorphism were more suitable for chemo-
therapy, while for ERCC2 rs13181, the polymorphism
had a null effect on the response to chemotherapy for
OS patients.
Despite there is only 3 cases of OS per 1,000,000 indi-
viduals, OS is the most primary malignant of bone
tumor worldwide occupying approximately 56% of all
bone tumors [22, 23]. It has been reported that OS arises
from mesenchymal cells undergoing abnormal modifica-
tions during the differentiation progress, which leads OS
to a heterogenic tumor [4]. With the usage of preopera-
tive and postoperative chemotherapy in clinic, the prog-
nosis of OS without metastasis has been improved
obviously, and the 5-year overall survival rate is elevated
to 77%, while the prognosis for patients with metastatic
OS is poor with a lower (less than 20%) 5-year overall
survival rate due to its resistance to conventional
chemotherapy [24]. Not only factors such as the age,
gender, and ethnicity impact on the incidence of OS, but
Table 1 Summary of characteristics of studies in the meta-analysis
Study Number of patients Treatment approaches Genotyping methods Age Male (%)
Z.H. Cao (2015) 186 Cisplatin-based chemotherapy PCR-RFLP 19.2 ± 9.4 57.53
Z.F. Liu (2015) 115 Cisplatin-based chemotherapy MALDI-TOF MS – 56.52
Y.J. Sun (2015) 175 Chemotherapy PCR-RFLP 17.8 ± 9.7 66.28
W.P. Ji (2015) 214 Cisplatin-based chemotherapy PCR-RFLP 18.7 ± 11.5 62.15
Q. Zhang (2015) 260 Cisplatin-based chemotherapy PCR-RFLP 18.4 ± 8.5 43.84
L.M. Yang(2012) 187 Neoadjuvant chemotherapy PCR-RFLP 17.7 ± 9.6 56.68
PCR-RFLP polymerase chain reaction restriction fragment length polymorphism assay, MALDI-TOF MS matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry method, – unavailable
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Fig. 2 Forest plot of study evaluating the relationship between the response to chemotherapy for OS patients and the ERCC1
rs11615 polymorphism
Fig. 3 Forest plot of study assessing the relationship between the response to chemotherapy for OS patients and the ERCC2
rs13181 polymorphism
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also genetic polymorphisms including CTLA-4 + 49A/G
and TGF-β1 29 T/C variants are reported to be signifi-
cantly correlated with OS susceptibility [25].
ERCC1, located at 19q13, encodes a rate-limiting en-
zyme in NER pathway, which can repair chemical drug-
induced DNA damage [26, 27]. The rs11615, one of the
common polymorphisms in ERCC1, may decrease the
expression of ERCC1 mRNA, thus reducing the resist-
ance to chemotherapy for cancer patients [26]. Cancer
cells overexpressing ERCC1 were correlated with drug
resistance to chemotherapy containing cisplatin, carbo-
platin, or oxaliplatin in several types of tumors such as
gastric, bladder, ovarian, colorectal, and lung carcinomas
[28]. Zhang et al. observed that the ERCC1 rs11615
polymorphism might influence the clinical outcomes
and response to chemotherapy for patients with OS, and
patients with CC genotype in ERCC1 rs11615 poly-
morphism had better response to chemotherapy [20]
which was also confirmed in our meta-analysis, we fur-
thermore incorporated all relevant data together and
considered OS patients with CC or TC + CC genotypes
had better response to chemotherapy. Thus, the genetic
polymorphism of rs11615 is a potentially alternative tar-
get for OS patients in clinical diagnosis, and the C allele
in ERCC1 rs11615 polymorphism for patients with OS
could be an underlying candidate predictor in clinical
chemotherapy treatment.
ERCC2, located at 9q13.3, encodes a DNA helicase
which causes repair of single-strand DNA injury [29].
ERCC2 gene possesses more than 500 SNPs, among which
rs13181 and rs1799793 are the two common polymor-
phisms that can alter the amino acid sequence in the
ERCC2 gene [30]. The ERCC2 rs13181 polymorphism has
been documented to be associated with a higher suscepti-
bility to glioma among the Chinese population [31]. And
the ERCC2 rs1799793 polymorphism, together with
ERCC1 rs11615 polymorphism, may play roles in the re-
sponse to chemotherapy and overall survival for patients
with gastric cancer [32]. As to the polymorphism in
ERCC2 for OS patients, Liu et al. found that the
rs1799793 polymorphism in ERCC2 gene was likely to in-
fluence the chemotherapy response, and OS patients with
AA genotype in ERCC2 rs1799793 were likely to have bet-
ter chemotherapy response, whereas the rs13181 poly-
morphism was not associated with the chemotherapy
response [17], which was not exactly the same as our re-
sults. We indicated that the polymorphism of rs13181 in
ERCC2 gene was also not correlated with the response to
chemotherapy for patients with OS. However, when enlar-
ging the sample size by pooling all related data together in
our meta-analysis, we detected that OS patients with AG
+AA genotype of rs1799793 polymorphism were more
likely to have good chemotherapy response which sug-
gested AG+AA genotype could be a potential predictor
for OS patients in clinical diagnosis and chemotherapeutic
treatment. What we found were significant supplements
to the molecular mechanism research of OS and will
greatly benefit the OS patients in the future.
Fig. 4 Forest plot of study estimating the relationship between the response to chemotherapy for OS patients and the ERCC2
rs1799793 polymorphism
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During the study retrieval, we found nine papers re-
garding the relationship between the chemotherapy
response and the rs11615, rs1799793, and rs13181
polymorphisms in ERCC1 and ERCC2 genes for OS
patients. Considering the different genetic and nation-
ality backgrounds, studies conducted on Spanish [33],
Slovenian [34] and Italian [7] populations were ex-
cluded, and only studies related to Chinese population
were included and incorporated to get a more reliable
and precise evaluation of the association between the
response to chemotherapy and the polymorphisms of
rs11615, rs1799793, and rs13181 in ERCC1 and
ERCC2 genes for patients with OS among Chinese
population.
To our knowledge, the present study is the first
meta-analysis to explore the correlation of the
chemotherapy response and the rs11615, rs1799793,
and rs13181 polymorphisms in ERCC1 and ERCC2
genes for OS patients among Chinese population.
However, there are some limitations in the current
study. Firstly, as we mentioned above, there is only
one article assessing the association between the re-
sponse to chemotherapy and the polymorphisms of
Fig. 5 Funnel plots of studies with ERCC1 rs11615 polymorphism
under dominant model (a), recessive model (b), and allelic model (c)
Fig. 6 Funnel plots of studies with ERCC2 rs13181 polymorphism
under dominant model (a), recessive model (b), and allelic model (c)
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rs11615, rs1799793, and rs13181 for OS patients for
three different nationalities including Spanish, Sloven-
ian, and Italian, respectively. Although, we performed
our meta-analysis on Chinese population with six
eligible studies incorporated, with more studies be-
coming available for other nationalities, the overall
meta-analysis and subgroup analysis stratified by na-
tionalities would be conducted. Secondly, the geno-
typing methods in the included studies were not
exactly the same, which might cause bias in our
meta-analysis. Additionally, unpublished articles were
not considered in our study.
Conclusions
The current meta-analysis suggested that for OS patients
among Chinese population, the rs11615 and rs1799793
polymorphisms were significantly associated with the
chemotherapy response, and patients with CC or TC +
CC genotypes in ERCC1 rs11615 polymorphism or AG
+AA genotype in ERCC2 rs1799793 polymorphism were
more likely to have good response to chemotherapy.
These SNPs may be candidate pharmacogenomic factors
capable of indentifying OS patients who are more appro-
priate to receive chemotherapy.
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